These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 31757595)
1. Efficacy of curcumin in the treatment of experimental vulvovaginal candidiasis. Andrade JT; Fantini de Figueiredo G; Cruz LF; Eliza de Morais S; Souza CDF; Pinto FCH; Ferreira JMS; Araújo MGF Rev Iberoam Micol; 2019; 36(4):192-199. PubMed ID: 31757595 [TBL] [Abstract][Full Text] [Related]
2. Formulation, stability study and preclinical evaluation of a vaginal cream containing curcumin in a rat model of vulvovaginal candidiasis. Fernandes LS; Amorim YM; da Silva EL; Silva SC; Santos AJA; Peixoto FN; Neves Pires LM; Sakamoto RY; Horta Pinto FDC; Scarpa MVC; Araújo MGF Mycoses; 2018 Oct; 61(10):723-730. PubMed ID: 29517833 [TBL] [Abstract][Full Text] [Related]
3. Novel Preclinical Study of Galloylquinic Acid Compounds from Al-Madboly LA; Abd El-Salam MA; Bastos JK; El-Shorbagy SH; El-Morsi RM Microbiol Spectr; 2022 Oct; 10(5):e0272421. PubMed ID: 35972130 [TBL] [Abstract][Full Text] [Related]
4. Curcumin-Loaded Liquid Crystalline Systems for Controlled Drug Release and Improved Treatment of Vulvovaginal Candidiasis. Rodero CF; Fioramonti Calixto GM; Cristina Dos Santos K; Sato MR; Aparecido Dos Santos Ramos M; Miró MS; Rodríguez E; Vigezzi C; Bauab TM; Sotomayor CE; Chorilli M Mol Pharm; 2018 Oct; 15(10):4491-4504. PubMed ID: 30184431 [TBL] [Abstract][Full Text] [Related]
5. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats. Martinez A; Ferrer S; Santos I; Jimenez E; Sparrowe J; Regadera J; De Las Heras FG; Gargallo-Viola D Antimicrob Agents Chemother; 2001 Dec; 45(12):3304-9. PubMed ID: 11709301 [TBL] [Abstract][Full Text] [Related]
6. Antifungal efficacy of atorvastatin-containing emulgel in the treatment of oral and vulvovaginal candidiasis. de Oliveira Neto AS; Souza ILA; Amorim MES; de Freitas Souza T; Rocha VN; do Couto RO; Fabri RL; de Freitas Araújo MG Med Mycol; 2021 May; 59(5):476-485. PubMed ID: 32823281 [TBL] [Abstract][Full Text] [Related]
7. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis. Nagashima M; Yamagishi Y; Mikamo H J Infect Chemother; 2016 Feb; 22(2):124-6. PubMed ID: 26627336 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Syngonanthus nitens (Bong.) Ruhl. extract as antifungal and in treatment of vulvovaginal candidiasis. de Freitas Araújo MG; Pacífico M; Vilegas W; Dos Santos LC; Icely PA; Miró MS; Scarpa MV; Bauab TM; Sotomayor CE Med Mycol; 2013 Oct; 51(7):673-82. PubMed ID: 23758104 [TBL] [Abstract][Full Text] [Related]
9. ROS mediated anticandidal efficacy of 3-Bromopyruvate prevents vulvovaginal candidiasis in mice model. Jothi R; Hong ST; Enkhtsatsral M; Pandian SK; Gowrishankar S PLoS One; 2023; 18(12):e0295922. PubMed ID: 38153954 [TBL] [Abstract][Full Text] [Related]
11. Proanthocyanidin polymeric tannins from Stryphnodendron adstringens are effective against Candida spp. isolates and for vaginal candidiasis treatment. de Freitas ALD; Kaplum V; Rossi DCP; da Silva LBR; Melhem MSC; Taborda CP; de Mello JCP; Nakamura CV; Ishida K J Ethnopharmacol; 2018 Apr; 216():184-190. PubMed ID: 29325916 [TBL] [Abstract][Full Text] [Related]
12. Amphotericin B-Loaded Poly(lactic-co-glycolic acid) Nanofibers: An Alternative Therapy Scheme for Local Treatment of Vulvovaginal Candidiasis. Souza RO; Henrique de Lima T; Oréfice RL; de Freitas Araújo MG; de Lima Moura SA; Magalhães JT; da Silva GR J Pharm Sci; 2018 Oct; 107(10):2674-2685. PubMed ID: 29940181 [TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents. Choukri F; Benderdouche M; Sednaoui P J Mycol Med; 2014 Dec; 24(4):303-7. PubMed ID: 25442913 [TBL] [Abstract][Full Text] [Related]
14. A comparative investigation of azole susceptibility in Candida isolates from vulvovaginal candidiasis and recurrent vulvovaginal candidiasis patients in Ghana. Adjapong G; Hale M; Garrill A Med Mycol; 2017 Aug; 55(6):686-689. PubMed ID: 27838642 [TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics and Antifungal Susceptibility of Candida nivariensis from Vulvovaginal Candidiasis. Shi Y; Zhu Y; Fan S; Vitagliano A; Liu X; Liao Y; Liang Y; Vitale SG Gynecol Obstet Invest; 2020; 85(1):88-93. PubMed ID: 31694024 [TBL] [Abstract][Full Text] [Related]
16. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.]. Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489 [TBL] [Abstract][Full Text] [Related]
17. In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species. Mondello F; De Bernardis F; Girolamo A; Cassone A; Salvatore G BMC Infect Dis; 2006 Nov; 6():158. PubMed ID: 17083732 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of carvacrol and eugenol as prophylaxis and treatment of vaginal candidiasis in an immunosuppressed rat model. Chami F; Chami N; Bennis S; Trouillas J; Remmal A J Antimicrob Chemother; 2004 Nov; 54(5):909-14. PubMed ID: 15456732 [TBL] [Abstract][Full Text] [Related]